Houston immuno-oncology company reaches next FDA milestone, heads to phase 2 trial - InnovationMap
A Houston immuno-oncology company has recently made major headway with the FDA, including both a fast track and an orphan drug designation. It will soon start a phase 2 trial of its promising cancer fighting innovation.| InnovationMap
